In the past decade, China’s drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.
As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to key opinion leaders, patients and hospitals, as it seeks to find solutions to diseases of high prevalence in Asia. The ICC has built on its wealth of scientific knowledge by establishing an extensive network of collaborations complementing this core expertise by developing long-standing relationships with external researchers in the field to benefit translational science and drug discovery, allowing new medicines to be developed faster.